163 related articles for article (PubMed ID: 19194115)
21. Papillary carcinoma of the thyroid gland of childhood and adolescence: Morphologic subtypes, biologic behavior and prognosis: a clinicopathologic study of 42 sporadic cases treated at a single institution during a 30-year period.
Collini P; Mattavelli F; Pellegrinelli A; Barisella M; Ferrari A; Massimino M
Am J Surg Pathol; 2006 Nov; 30(11):1420-6. PubMed ID: 17063083
[TBL] [Abstract][Full Text] [Related]
22. Cyclin D1 overexpression in thyroid papillary microcarcinoma: its association with tumour size and aberrant beta-catenin expression.
Lantsov D; Meirmanov S; Nakashima M; Kondo H; Saenko V; Naruke Y; Namba H; Ito M; Abrosimov A; Lushnikov E; Sekine I; Yamashita Sh
Histopathology; 2005 Sep; 47(3):248-56. PubMed ID: 16115225
[TBL] [Abstract][Full Text] [Related]
23. Large deletions in mitochondrial DNA in radiation-associated human thyroid tumors.
Rogounovitch TI; Saenko VA; Shimizu-Yoshida Y; Abrosimov AY; Lushnikov EF; Roumiantsev PO; Ohtsuru A; Namba H; Tsyb AF; Yamashita S
Cancer Res; 2002 Dec; 62(23):7031-41. PubMed ID: 12460924
[TBL] [Abstract][Full Text] [Related]
24. Cyclin D1 expression in primary thyroid carcinomas.
Sporny S; Slowinska-Klencka D; Ratynska M
Neuro Endocrinol Lett; 2005 Dec; 26(6):815-8. PubMed ID: 16380680
[TBL] [Abstract][Full Text] [Related]
25. Altered expression of cyclins and cell cycle inhibitors in papillary thyroid cancer: prognostic implications.
Pickett CA; Agoff SN; Widman TJ; Bronner MP
Thyroid; 2005 May; 15(5):461-73. PubMed ID: 15929668
[TBL] [Abstract][Full Text] [Related]
26. Array CGH demonstrates characteristic aberration signatures in human papillary thyroid carcinomas governed by RET/PTC.
Unger K; Malisch E; Thomas G; Braselmann H; Walch A; Jackl G; Lewis P; Lengfelder E; Bogdanova T; Wienberg J; Zitzelsberger H
Oncogene; 2008 Jul; 27(33):4592-602. PubMed ID: 18408749
[TBL] [Abstract][Full Text] [Related]
27. Minichromosome maintenance protein 3 is a candidate proliferation marker in papillary thyroid carcinoma.
Lee YS; Ha SA; Kim HJ; Shin SM; Kim HK; Kim S; Kang CS; Lee KY; Hong OK; Lee SH; Kwon HS; Cha BY; Kim JW
Exp Mol Pathol; 2010 Feb; 88(1):138-42. PubMed ID: 19818763
[TBL] [Abstract][Full Text] [Related]
28. Expression of S100A2 and S100A6 in thyroid carcinomas.
Ito Y; Yoshida H; Tomoda C; Uruno T; Miya A; Kobayashi K; Matsuzuka F; Kakudo K; Kuma K; Miyauchi A
Histopathology; 2005 May; 46(5):569-75. PubMed ID: 15842639
[TBL] [Abstract][Full Text] [Related]
29. Expression of the melanoma-associated antigen is associated with progression of human thyroid cancer.
Cheng S; Liu W; Mercado M; Ezzat S; Asa SL
Endocr Relat Cancer; 2009 Jun; 16(2):455-66. PubMed ID: 19261683
[TBL] [Abstract][Full Text] [Related]
30. CD147 expression as a significant prognostic factor in differentiated thyroid carcinoma.
Tan H; Ye K; Wang Z; Tang H
Transl Res; 2008 Sep; 152(3):143-9. PubMed ID: 18774544
[TBL] [Abstract][Full Text] [Related]
31. The FOXE1 locus is a major genetic determinant for radiation-related thyroid carcinoma in Chernobyl.
Takahashi M; Saenko VA; Rogounovitch TI; Kawaguchi T; Drozd VM; Takigawa-Imamura H; Akulevich NM; Ratanajaraya C; Mitsutake N; Takamura N; Danilova LI; Lushchik ML; Demidchik YE; Heath S; Yamada R; Lathrop M; Matsuda F; Yamashita S
Hum Mol Genet; 2010 Jun; 19(12):2516-23. PubMed ID: 20350937
[TBL] [Abstract][Full Text] [Related]
32. Molecular phenotyping of thyroid tumors identifies a marker panel for differentiated thyroid cancer diagnosis.
Wiseman SM; Melck A; Masoudi H; Ghaidi F; Goldstein L; Gown A; Jones SJ; Griffith OL
Ann Surg Oncol; 2008 Oct; 15(10):2811-26. PubMed ID: 18612701
[TBL] [Abstract][Full Text] [Related]
33. Analysis of deregulated miRNAs is helpful to distinguish poorly differentiated thyroid carcinoma from papillary thyroid carcinoma.
Schwertheim S; Sheu SY; Worm K; Grabellus F; Schmid KW
Horm Metab Res; 2009 Jun; 41(6):475-81. PubMed ID: 19370508
[TBL] [Abstract][Full Text] [Related]
34. Immunohistochemical expression of pl30cas in papillary thyroid carcinoma.
Dilek FH; Aktepe F; Sahin DA; Topak N; Dilek ON
Int Surg; 2008; 93(3):175-80. PubMed ID: 18828274
[TBL] [Abstract][Full Text] [Related]
35. Short telomeres, telomerase reverse transcriptase gene amplification, and increased telomerase activity in the blood of familial papillary thyroid cancer patients.
Capezzone M; Cantara S; Marchisotta S; Filetti S; De Santi MM; Rossi B; Ronga G; Durante C; Pacini F
J Clin Endocrinol Metab; 2008 Oct; 93(10):3950-7. PubMed ID: 18664542
[TBL] [Abstract][Full Text] [Related]
36. The expression of sialic fibronectin correlates with lymph node metastasis of thyroid malignant neoplasmas.
Takeyama H; Kyoda S; Okamoto T; Manome Y; Watanabe M; Kinoshita S; Uchida K; Sakamoto A; Morikawa T
Anticancer Res; 2011 Apr; 31(4):1395-8. PubMed ID: 21508391
[TBL] [Abstract][Full Text] [Related]
37. CLIP2 as radiation biomarker in papillary thyroid carcinoma.
Selmansberger M; Feuchtinger A; Zurnadzhy L; Michna A; Kaiser JC; Abend M; Brenner A; Bogdanova T; Walch A; Unger K; Zitzelsberger H; Hess J
Oncogene; 2015 Jul; 34(30):3917-25. PubMed ID: 25284583
[TBL] [Abstract][Full Text] [Related]
38. High recurrent rate of multicentric papillary thyroid carcinoma.
Lin JD; Chao TC; Hsueh C; Kuo SF
Ann Surg Oncol; 2009 Sep; 16(9):2609-16. PubMed ID: 19533244
[TBL] [Abstract][Full Text] [Related]
39. RET proto-oncogene expression of papillary thyroid carcinomas in Thai patients.
Keelawat S; Shuangshoti S; Assanasen T; Thanakit V; Ruangvejvorachai P; Poumsuk U; Wannakrairot P
J Med Assoc Thai; 2006 Sep; 89 Suppl 3():S5-12. PubMed ID: 17718263
[TBL] [Abstract][Full Text] [Related]
40. Thyroid peroxidase and galectin-3 immunostaining in differentiated thyroid carcinoma with clinicopathologic correlation.
Savin S; Cvejic D; Isic T; Paunovic I; Tatic S; Havelka M
Hum Pathol; 2008 Nov; 39(11):1656-63. PubMed ID: 18657294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
